Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC40A1 | Q9NP59 | 8/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 4/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.43 |
| ▸ | GHSR | Q92847 | 2/20 | 0.41 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27214298 | 1.00 | SLC40A1 (0.63) | SLC40A1ALDH1A1POLBTSHRMEN1 | |
| SCHEMBL26964227 | 0.84 | SLC40A1 (0.61) | SLC40A1MEN1KMT2A | |
| SCHEMBL30925399 | 0.79 | SLC40A1 (0.58) | SLC40A1ALDH1A1MEN1KMT2AAGTR1 | |
| SCHEMBL27214174 | 0.79 | SLC40A1 (0.58) | SLC40A1ALDH1A1MEN1KMT2AAGTR1 | |
| SCHEMBL30925398 | 0.78 | SLC40A1 (0.51) | SLC40A1ALDH1A1MEN1KMT2AAGTR1 | |
| SCHEMBL11973715 | 0.77 | SLC40A1 (1.00) | SLC40A1ALDH1A1POLBMEN1KMT2A | |
| SCHEMBL27214305 | 0.74 | SLC40A1 (0.49) | SLC40A1ALDH1A1POLBTSHRMEN1 | |
| SCHEMBL27214314 | 0.73 | SLC40A1 (0.65) | SLC40A1ALDH1A1POLBTSHRMEN1 | |
| SCHEMBL30925454 | 0.70 | SLC40A1 (0.61) | SLC40A1ALDH1A1POLBTSHRMEN1 | |
| SCHEMBL26964313 | 0.70 | SLC40A1 (0.61) | SLC40A1ALDH1A1POLBTSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ZOETIS LLC | 2024-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240148744-A1 | SULFONAMIDES AND THEIR USE FOR TREATMENT OF HELMINTHIC INFECTIONS AND DISEASES | ARSA, MRPS2, SULT2A1 | SLC40A1 3357/4885ALDH1A1 1470/4885POLB 3189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.